PRPH | ProPhase Labs, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.4000 - 2.7178
52 Week Range	2.0400 - 7.48
Beta	-0.11
Implied Volatility	288.02%
IV Rank	28.98%
Day's Volume	29,496
Average Volume	30,798
Shares Outstanding	19,078,500
Market Cap	45,788,400
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	1994-04-04

Valuation
Profitability
Growth
Health
P/E Ratio	-1.62
Forward P/E Ratio	7.50
EPS	-1.48
1YR Price Target	15.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	113
Country	USA
Website	PRPH

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

PRPH's peers: OCX, LMDX, STRR, ENZ, GTH, STIM, INBS, BDSX, PRPO, DRIO, OLK, XGN, SHC, BNR, PMD, SERA, XTLB

*Chart delayed

Analyzing fundamentals for PRPH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see PRPH Fundamentals page.

Watching at PRPH technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PRPH Technicals page.